Navigation Links
PELOBIOTECH to Distribute ReachBio's Products in Germany, Austria and Switzerland
Date:10/28/2013

SEATTLE, Oct. 28, 2013 /PRNewswire/ -- ReachBio LLC (Seattle, WA, USA) announced today that it has signed an agreement with PELOBIOTECH GmbH (Munich, Germany) giving PELOBIOTECH exclusive distribution rights to ReachBio's full product line for the life science research market within Germany, Austria and Switzerland.

(Logo: http://photos.prnewswire.com/prnh/20131028/SF04854LOGO)

ReachBio provides research products and contract services for applications in basic life science research, drug research & development and toxicology. The company's main product lines consist of ColonyGEL™ methylcellulose-based media for hematopoietic colony-forming cell (CFC) assays and cryopreserved normal human primary cells isolated from blood, cord blood and bone marrow.

The extensive ColonyGEL™ semi-solid media product line includes multiple formulations with different cytokine (growth factor) combinations optimized for the growth of the different progenitor cells in blood and bone marrow. In the cytokine-optimized, semi-solid environment provided by ColonyGEL™, the different progenitors grow as morphologically distinct three-dimensional colonies that can be identified and scored microscopically. The ColonyGEL™ line-up also includes formulations optimized for different species, including human, mouse, rat, dog and non-human primate.  Applications of CFC assays using ColonyGEL™ media include research into normal and abnormal hematological development, leukemia and cancer stem cells, cell therapy, stem cell biology, investigative toxicology, etc.

ReachBio's line of normal primary human cells include highly purified cell types from blood such as the various subsets of T lymphocytes, B lymphocytes, natural killer cells and monocytes. It also includes "ReachBio Qualified" CD34+ and CD133+ stem cells/primitive progenitors purified from cord blood and bone marrow that have been pre-qualified in CFC assays. ReachBio also specializes in providing customized cell isolation services for customers with specific needs such as unique cell types, particular donor background or HLA type, repeat donor cell isolations, and/or customized vial sizes.

"ReachBio is extremely happy to have PELOBIOTECH representing our products in Germany, Austria and Switzerland," said Rob Chaney, ReachBio's General Manager and COO. "We have known Peter Frost, one of the founders of PELOBIOTECH, for many years and have the utmost respect for him and his knowledge of the life science research market within these research intensive countries. He has already been aiding ReachBio's sales and business development efforts for our specialized cell biology contract research services in this same territory for the last few years with great results. So having him and PELOBIOTECH now representing our products as well is a great fit and makes perfect sense."

Said Dr. Peter Frost, CEO of PELOBIOTECH, "We are delighted to now be distributing ReachBio's ColonyGEL™ and normal human cell products. The high quality of these products reflects the reputation for quality and value that ReachBio has built regarding both its contract research services and its products. ColonyGEL™ provides researchers performing CFC assays a great alternative to the methylcellulose-based media provided by the leading competitor, which has become quite overpriced through many years of price increases. Additionally, we are happy that ReachBio is able to provide not only standard vials of high quality cryopreserved human cells but also flexible customized offerings. This is a great advantage to pharma companies that often have unique requirements for specific types of cells and a strong need for vial-to-vial and lot-to-lot reproducibility. This fits in very well with PELOBIOTECH's goal to provide customized solutions to aid our customers' research."

About ReachBio LLC
ReachBio LLC is a life sciences organization based in Seattle, WA. It provides specialized contract research services and products to biopharmaceutical, biotechnology, and related organizations worldwide.

About PELOBIOTECH GmbH
PELOBIOTECH GmbH is based in Martinsried (near Munich), Germany and is a local distributor of high quality life science research tools and reagents with a focus on primary cell and stem cell biology,  3D cell culture and media development for human primary cells.


'/>"/>
SOURCE ReachBio LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirtex To Distribute Surefire Medicals Innovative Infusion System in Australia and Asia Pacific Markets
2. Independent Pharmacy Cooperative to Distribute Promescent, Topical Medication for Premature Ejaculation
3. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
4. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
5. GHX Selects MicroStrategy to Offer Healthcare Suppliers Enhanced Access to Distributed Medical-Surgical Market Data
6. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software
7. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Volpara Breast Density Software
8. Hcg-injections.co is a website that provides HCG injections and vitamin B12 injections. These products taken under prescription help customers lose weight. The website is secure and process orders within the same working day and delivers promptly
9. Mindray Medical to Exhibit New Products at Upcoming Medical Equipment Fairs
10. Univar Announces Distribution Agreement with Swati Spentose for Lidocaine Products
11. Anti-Adhesion Products - Global Strategic Business Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced ... report to their offering. ... , The report provides separate comprehensive ... , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology:
(Date:12/8/2016)... NC (PRWEB) , ... December 08, 2016 , ... ... Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass media ... story movement gives people ongoing opportunities to share their unfortunate experiences; such a ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that serve communities in and around the greater Phoenix metropolitan region, is announcing ... Connection. , The mission of the Homeless Youth Connection is to promote community ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication ... one of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department ... on both sides of the Atlantic with a mechanism to comply with EU data ...
(Date:12/7/2016)... Orleans, LA (PRWEB) , ... December 07, 2016 ... ... technique used to treat wrinkles and deep lines by smoothing and tightening the ... minimally invasive techniques out there to address facial aging with very little downtime, ...
(Date:12/7/2016)... ... 07, 2016 , ... It is vital for any lab to secure funding, ... The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to ... to operate in a GLP (Good Laboratory Practice) fashion. , With features designed to ...
Breaking Medicine News(10 mins):